The BCG replacement vaccine VPM1002: from drawing board to clinical trial
SHE Kaufmann, MF Cotton, B Eisele… - Expert review of …, 2014 - Taylor & Francis
Tuberculosis remains a major health threat and vaccines better than bacillus Calmette-
Guérin (BCG) are urgently required. Here we describe our experience with a recombinant …
Guérin (BCG) are urgently required. Here we describe our experience with a recombinant …
Recombinant live vaccine candidates against tuberculosis
SHE Kaufmann, M Gengenbacher - Current opinion in biotechnology, 2012 - Elsevier
Tuberculosis (TB) remains among the most deadly health threats to humankind despite
availability of several potent antibiotics and a vaccine, bacille Calmette-Guérin (BCG). BCG …
availability of several potent antibiotics and a vaccine, bacille Calmette-Guérin (BCG). BCG …
Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines
T Hanke - Expert opinion on biological therapy, 2014 - Taylor & Francis
Introduction: Effective vaccines are the best solution for stopping the spread of HIV/AIDS and
other infectious diseases. Their development and in-depth understanding of pathogen–host …
other infectious diseases. Their development and in-depth understanding of pathogen–host …
Immunization with a recombinant bacillus Calmette–Guérin strain confers protective Th1 immunity against the human metapneumovirus
CE Palavecino, PF Céspedes, RS Gómez… - The Journal of …, 2014 - journals.aai.org
Along with the human respiratory syncytial virus (hRSV), the human metapneumovirus
(hMPV) is one of the leading causes of childhood hospitalization and a major health burden …
(hMPV) is one of the leading causes of childhood hospitalization and a major health burden …
Thirty years of recombinant BCG: new trends for a centenary vaccine
LM Marques-Neto, Z Piwowarska, AI Kanno… - Expert Review of …, 2021 - Taylor & Francis
Introduction: Global perception of the potential for Bacille Calmette-Guérin (BCG), and
consequently recombinant BCG (rBCG), in a variety of prophylactic and therapeutic …
consequently recombinant BCG (rBCG), in a variety of prophylactic and therapeutic …
MTBVAC-based TB-HIV vaccine is safe, elicits HIV-T cell responses, and protects against Mycobacterium tuberculosis in mice
The tuberculosis (TB) vaccine MTBVAC is the only live-attenuated Mycobacterium
tuberculosis (Mtb)-based vaccine in clinical development, and it confers superior protection …
tuberculosis (Mtb)-based vaccine in clinical development, and it confers superior protection …
Pathogen-specific T cell depletion and reactivation of opportunistic pathogens in HIV infection
C Geldmacher, RA Koup - Trends in immunology, 2012 - cell.com
During HIV infection, it is unclear why different opportunistic pathogens cause disease at
different CD4 T cell count thresholds. Early work has shown that CD4 T cell depletion is …
different CD4 T cell count thresholds. Early work has shown that CD4 T cell depletion is …
Priming with recombinant BCG expressing novel HIV-1 conserved mosaic immunogens and boosting with recombinant ChAdOx1 is safe, stable, and elicits HIV-1 …
A Kilpeläinen, N Saubi, N Guitart, N Moyo… - Frontiers in …, 2019 - frontiersin.org
BCG is currently the only licensed vaccine against tuberculosis (TB) and confers protection
against meningitis and miliary tuberculosis in infants, although pulmonary disease …
against meningitis and miliary tuberculosis in infants, although pulmonary disease …
Mucosal SIV Vaccines Comprising Inactivated Virus Particles and Bacterial Adjuvants Induce CD8+ T-Regulatory Cells that Suppress SIV-Positive CD4+ T-Cell …
JM Andrieu, S Chen, C Lai, W Guo, W Lu - Frontiers in immunology, 2014 - frontiersin.org
A new paradigm of mucosal vaccination against human immunodeficiency virus (HIV)
infection has been investigated in the macaque model. A vaccine consisting of inactivated …
infection has been investigated in the macaque model. A vaccine consisting of inactivated …
Justification for the inclusion of Gag in HIV vaccine candidates
AL Williamson, EP Rybicki - Expert review of vaccines, 2016 - Taylor & Francis
It is widely accepted that effective human immunodeficiency virus (HIV) vaccines need to
elicit a range of responses, including neutralising antibodies and T-cells. In natural HIV …
elicit a range of responses, including neutralising antibodies and T-cells. In natural HIV …